

May 8, 2012

## **Theravance to Webcast 2012 Annual Meeting of Stockholders on May 15, 2012**

SOUTH SAN FRANCISCO, Calif., May 8, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:[THR](#)) announced today that it will webcast its 2012 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on Tuesday, May 15, 2012.

An accompanying listen-only conference call will be held at 4:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. Those interested in listening to the audio feed live via the internet may do so by visiting the company's web site at [www.theravance.com](http://www.theravance.com). To listen to the live call and download the presentation, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the 2012 Annual Meeting of Stockholders will be available on the company's web site for 30 days through June 14, 2012. A telephone replay will also be available through 11:59 p.m. Eastern Daylight Time on May 22, 2012 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering confirmation code 71071355.

### **About Theravance**

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELOVAIR™, LAMA/LABA (719/vilanterol (VI)) and MABA (Bifunctional Muscarinic Antagonist-Beta<sub>2</sub> Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist (PμMA) program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at [www.theravance.com](http://www.theravance.com).

The Theravance logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=3908>

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

RELOVAIR™ is a trademark of the GlaxoSmithKline group of companies.

CONTACT: Michael W. Aguiar  
Senior Vice President and Chief Financial Officer  
650-808-4100  
[investor.relations@theravance.com](mailto:investor.relations@theravance.com)